![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Relmada Wins FDA Fast Track Designation for d-Methadone
Relmada Wins FDA Fast Track Designation for d-Methadone
April 20, 2017
Relmada Therapeutics received an FDA fast track designation for d-Methadone (REL-1017 dextromethadone), a receptor antagonist in development for the adjunctive treatment of major depressive disorder.
REL-1017 is a new chemical entity being developed as an oral agent for the treatment of depression, neuropathic pain and other potential CNS pathological conditions. The company has completed Phase I single and multiple ascending dose studies and has confirmed safety, tolerability and dose range for planned Phase II studies in treatment-resistant depression.
Relmada is planning a Phase IIa placebo-controlled study in patients with major depressive disorder, assessing changes in depressive symptoms as well as the safety, tolerability and pharmacokinetics of two dose levels of REL-1017.
Upcoming Events
-
21Oct